interaction of FK-506 with KV1.3, stably expressed in Chinese hamster ovary cells, was investigated with the whole cell patch-clamp technique. FK-506 inhibited K V1.3 in a reversible, concentrationdependent manner with an IC50 of 5.6 M. Rapamycin, another immunosuppressant, produced effects that were similar to those of FK-506 (IC50 ϭ 6.7 M). Other calcineurin inhibitors (cypermethrin or calcineurin autoinhibitory peptide) alone had no effect on the amplitude or kinetics of KV1.3. In addition, the inhibitory action of FK-506 continued, even after the inhibition of calcineurin activity. The inhibition produced by FK-506 was voltage dependent, increasing in the voltage range for channel activation. At potentials positive to 0 mV (where maximal conductance is reached), however, no voltagedependent inhibition was found. FK-506 exhibited a strong usedependent inhibition of K V1.3. FK-506 shifted the steady-state inactivation curves of KV1.3 in the hyperpolarizing direction in a concentration-dependent manner. The apparent dissociation constant for FK-506 to inhibit KV1.3 in the inactivated state was estimated from the concentration-dependent shift in the steady-state inactivation curve and was calculated to be 0.37 M. Moreover, the rate of recovery from inactivation of KV1.3 was decreased. In inside-out patches, FK-506 not only reduced the current amplitude but also accelerated the rate of inactivation during depolarization. FK-506 also inhibited KV1.5 and KV4.3 in a concentration-dependent manner with IC50 of 4.6 and 53.9 M, respectively. The present results indicate that FK-506 inhibits KV1.3 directly and that this effect is not mediated via the inhibition of the phosphatase activity of calcineurin. potassium channel; immunosuppressant; calcineurin inhibitor is a potent immunosuppressant that is widely used to prevent rejection after organ transplantation and in the treatment of various autoimmune diseases (13, 26) . FK-506 binds to FK-506 binding protein (FKBP), a cytosolic protein, and the resulting FK-506-FKBP complex inhibits the action of calcineurin, a Ca 2ϩ
potassium channel; immunosuppressant; calcineurin inhibitor FK-506 (TACROLIMUS) is a potent immunosuppressant that is widely used to prevent rejection after organ transplantation and in the treatment of various autoimmune diseases (13, 26) . FK-506 binds to FK-506 binding protein (FKBP), a cytosolic protein, and the resulting FK-506-FKBP complex inhibits the action of calcineurin, a Ca 2ϩ / calmodulin-dependent phosphatase 2B, subsequently preventing calcineurin-dependent interleukin (IL)-2 transcription and T lymphocyte activation (24, 36, 45) . Thus the mechanism of immunosuppressive action in these cells is thought to be mediated by a calcineurindependent mechanism. K V 1.3, a member of the Shaker family of voltage-gated K ϩ channels, is a delayed-rectifier channel (41) . K V 1.3 currents display characteristic gating kinetics: under whole cell patch-clamp conditions, K V 1.3 is activated within a few milliseconds in response to depolarizing pulses and undergoes a slow C-type inactivation during prolonged depolarization (9) . Because K V 1.3 recovers from inactivation extremely slowly, cumulative inactivation occurs after a train of repetitive pulses (25) . K V 1.3 is found in many tissues, specifically in lymphocytes and the brain (41) . In human T lymphocytes, it sets the cell membrane potential and controls the efflux of K ϩ necessary to maintain Ca 2ϩ influx (3) . Therefore, K V 1.3 is a primary regulator of T lymphocyte activation and is widely recognized as a potential target for immunotherapy (14) .
Calcineurin is known to have a variety of cellular functions in different types of cells such as neurotransmitter release, the activity of several ion channels, synaptic plasticity, and nerve regeneration (37, 47) . Immunosuppressants such as FK-506 and cyclosporin A (CsA), calcineurin inhibitors, also regulate the activity of ion channels. For example, FK-506 and CsA block high-voltage-activated Ca 2ϩ channels in cultured hippocampal neurons via a calcineurin-dependent mechanism (27) . It has been reported that both drugs act in a similar manner on voltage-activated Ca 2ϩ channels in hippocampal neurons and coronary arterial smooth muscle cells (29, 48) . In addition, the inhibition of calcineurin by FK-506 and CsA causes the upregulation of cell surface functional Na ϩ channels in adrenal chromaffin cells (35) . In contrast, CsA reduces the functional expression of K ir 2.1 K ϩ channels and nicotinic and 5-HT 3 receptors to a significant extent (4, 16, 17) . These effects are mediated by inhibition of the activation of the calcineurin-dependent pathway. However, several studies have alluded to the possibility that FK-506 has a direct and nonspecific effect on membrane structures and function in different cells. FK-506 inhibits outward K ϩ currents that are responsible for the repolarization of the action potentials in rat ventricular myocytes (10, 11) and modulates the single-channel activity of Ca 2ϩ -dependent K ϩ channels via a calcineurin-independent mechanism (44) . In addition, FK-506 blocks the voltage-gated K ϩ current, resulting in a time-dependent and rapid membrane depolarization in human T lymphocytes by a yet-to-be defined mechanism (31) . These results also raise the possibility that FK-506 modulates ion channel activity via mechanisms that do not involve effects on calcineurin. Although these observations suggest the possibility of the direct blocking action of FK-506 on voltage-gated K ϩ channels, the mechanism responsible and the effect on the kinetics of the channels are not well understood. Therefore, in the present study, we examined the effects of FK-506 on the cloned K ϩ channel K V 1.3 to investigate the direct action and detailed kinetics between the drug and the channel.
EXPERIMENTAL PROCEDURES
Stable transfection and cell culture. Chinese hamster ovary (CHO) cells (American Type Culture Collection, Rockville, MD) were maintained in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine serum, 0.1 mM hypoxanthine, and 0.01 mM thymidine in a humidified 5% CO 2 incubator at 37°C. The CHO cells used stably expressed K V1.3, K V1.5, or KV4.3 channels as previously described (5, 7, 28) . The cultures were exchanged at 2-to 3-day intervals with fresh IMDM containing 0.3 mg/ml of geneticin (Invitrogen) and passed every 2-3 days with the use of a brief trypsin-EDTA treatment. The trypsin-EDTA-treated cells were seeded onto glass coverslips (diameter 12 mm, Fisher Scientific, Pittsburgh, PA) in a petri dish 24 h before use. For electrophysiological recordings, coverslips with attached cells were transferred to a continually perfused recording chamber (RC-13, Warner Instrument, Hamden, CT).
Electrophysiological recordings. Currents were recorded at room temperature (22-24°C) with the whole cell and inside-out configuration of the patch-clamp technique with an Axopatch 200B patchclamp amplifier (Molecular Devices, Sunnyvale, CA). Micropipettes were pulled from PG10165-4 glass capillary tubing (World Precision Instruments, Sarasota, FL) and had resistances of 2-3 M⍀ when filled with internal pipette solution. The liquid junction potentials between the external and pipette solution were offset before the pipette made contact with the cell. The micropipettes were gently lowered onto the cells, and gigaohm seal formation was achieved by applying suction. After pipette capacitance compensation, the cells were ruptured by application of a brief additional suction. Seal resistances were in the range of 4 -10 G⍀. Thereafter, whole cell capacitative currents were compensated with analog compensation without leakage compensation. In the whole cell configuration, series resistances were ϳ4-8 M⍀. The effective series resistances were usually compensated by 80% if the current exceeded 1 nA. The sampling frequency was 5 kHz, and the currents were filtered at 2 kHz (4-pole Bessel filter) before being digitized. Data acquisition and analysis were performed on an IBM Pentium computer with pCLAMP 9.0 software (Molecular Devices).
Solutions and drugs. The bath solution contained (mM) 140 NaCl, 5 KCl, 1 CaCl 2, 1 MgCl2, and 10 HEPES and was adjusted to pH 7.3 with NaOH. This bath solution was used as the internal pipette solution for the inside-out recordings. The internal pipette solution contained (in mM) 140 KCl, 1 CaCl 2, 1 MgCl2, 10 HEPES, and 10 EGTA and was adjusted to pH 7.3 with KOH. This pipette solution was used as the bath solution for the inside-out recordings. During the recording, the cells were continuously perfused at a rate of 1 ml/min with normal bath solution. Drugs were applied to the bath via a gravity-fed perfusion system. Stock solutions of FK-506 and rapamycin (Calbiochem, San Diego, CA) were prepared in dimethyl sulfoxide (DMSO). A stock solution of cypermethrin (Calbiochem) in DMSO was also prepared. The concentration of DMSO in the final dilution was Ͻ0.1%, and this concentration had no effect on the KV1.3, KV1.5, and KV4.3 currents. Calcineurin autoinhibitory peptide (Calbiochem) was dissolved in distilled water and added directly to the internal pipette solution.
Data analysis. For analysis, Origin 7.0 software (OriginLab, Northampton, MA) was used. The concentration-response data were fitted to the Hill equation 
where V is the preconditioning potential and V 1 ⁄2 and k are the potential corresponding to the half-inactivation point (in mV) and the slope value (in mV), respectively. The time courses of current inactivation during the depolarizing pulses were fitted to a single exponential function. Data are expressed as means Ϯ SE. One-way analysis of variance, followed by Bonferroni test, was used to evaluate the statistical significance of the observed differences (46) . Statistical significance was considered at P Ͻ 0.05 with Origin 7.0 software (OriginLab).
RESULTS

Concentration-dependent inhibition of K V 1.3 by FK-506 and rapamycin.
In the whole cell configuration, no appreciable endogenous currents were detected in nontransfected CHO cells, as described previously (6, 33) . Figure 1A shows the superimposed K V 1.3 current traces as the result of a 200-ms depolarizing pulse to ϩ40 mV under control conditions and in the presence of FK-506. In the absence of the drug, the K V 1.3 currents were rapidly activated, reached a peak value, and then were slowly inactivated while the depolarizing pulse was maintained, as described previously (7, 25) . When applied to the external bath solution, FK-506 (1, 3, 10, and 30 M) not only reduced the peak amplitude of the current but also altered the time course for current decay, increasing the rate of current decay during depolarization at the concentrations used. Under control conditions, the current decay of K V 1.3 was well fitted to a single exponential function with a time constant of 166.3 Ϯ 9.5 ms (n ϭ 11). After the addition of FK-506, the apparent inactivation of K V 1.3 was accelerated with time constants of 141.5 Ϯ 7.5, 114.5 Ϯ 8.6, 75.5 Ϯ 7.6, and 38.8 Ϯ 4.3 ms (n ϭ 11) for 1, 3, 10, and 30 M, respectively. Thus the peak amplitude of the current was affected much less than the steady-state current amplitude at the end of the 200-ms depolarizing pulse. The current amplitude measured at the end of the 200-ms depolarizing pulse to ϩ40 mV was used as an index of the inhibition. A nonlinear least-squares fit of the Hill equation to the concentration-response data yielded an IC 50 value of 5.6 Ϯ 0.7 M and n H of 1.5 Ϯ 0.1 (n ϭ 11) for FK-506 at ϩ40 mV.
We further examined the effects of another immunosuppressant, rapamycin, on K V 1.3 currents (Fig. 1B) . Similar to FK-506, rapamycin enhanced the rate of current decay, resulting in a decrease in current amplitude at the end of a 200-ms depolarizing pulse. Figure  1B shows the concentration dependence for the rapamycin-induced inhibition of K V 1.3 measured at the end of the 200-ms depolarizing pulse. A nonlinear least-squares fit of the Hill equation to the concentration-response data yielded an IC 50 value of 6.7 Ϯ 0.8 M and n H of 1.3 Ϯ 0.1 (n ϭ 6) at ϩ40 mV. Thus the potency of rapamycin was similar to that of FK-506 in inhibiting the K V 1.3 current.
To assess the reversibility of the effect of the drug, the single depolarizing pulse was repeated while 5 M FK-506 was applied. As shown in Fig. 2 , when solutions were switched to solutions containing the drug, steady-state inhibition of K V 1.3 was reached within 2 min. The washout of FK-506 by perfusion with a drug-free solution was also complete within 3 min. The currents recovered to 93.1 Ϯ 2.4% (n ϭ 9) of the control from the steady-state inhibition by FK-506. Therefore, the inhibition was reversible on washout, with little rundown in the current being observed under these conditions.
Effects of calcineurin inhibitors on inhibition of K V 1.3 by FK-506. The K V 1.3 channel can be phosphorylated and dephosphorylated (8, 32, 40) , and FK-506 has been reported to function as a phosphatase inhibitor (45) . To determine whether calcineurin is involved in the FK-506-induced inhibition of K V 1.3, we investigated the effects of other calcineurin inhibitors, such as cypermethrin in the bath solution and calcineurin autoinhibitory peptide in the pipette solution. Figure 3A shows the effects of cypermethrin on the inhibition of K V 1.3 by FK-506. After a 30-min preincubation with 40 nM cypermethrin, 5 M FK-506 inhibited the steady-state current of K V 1.3, measured at the end of a depolarizing pulse of ϩ40 mV, by 59.3 Ϯ 0.9% (n ϭ 4). Figure 3B shows the effects of 100 M calcineurin autoinhibitory peptide in the pipette solution. Over a 10-min period after membrane rupture, cell dialysis with a pipette solution containing calcineurin autoinhibitory peptide produced no effect on the amplitude or kinetics of K V 1.3 compared with the control measured immediately after membrane rupture. With addition of 5 M FK-506 to the bath solution, the steady-state current of K V 1.3 was decreased by 50.7 Ϯ 1.2% (n ϭ 7). The lack of effect of cypermethrin and calcineurin autoinhibitory peptide on the FK-506-induced inhibition of K V 1.3 strongly indicates that FK-506 directly inhibits K V 1.3 via a calcineurin-independent mechanism.
Voltage-dependent inhibition of K V 1.3 by FK-506. Figure 4 shows the effect of FK-506 on the current-voltage (I-V) relationship. Under control conditions, the I-V relationship was almost linear for depolarizing pulses between Ϫ40 and ϩ40 mV (Fig. 4, A and C) . In the presence of 5 M FK-506, the steady-state currents were inhibited over the entire voltage range in which K V 1.3 was activated, as shown in Fig. 4 , B and C. In a plot of the relative current (I FK-506 /I Control ) versus potential (Fig. 4D) , the inhibition of K V 1.3 by FK-506 increased steeply between Ϫ30 and Ϫ10 mV, which corresponded with the voltage range for channel activation (F 2,21 ϭ 11.7, P Ͻ 0.01). However, the inhibition in the voltage range between 0 and ϩ40 mV, where the channels are fully activated, did not show any voltage dependence. The linear curve fitting of the data at potentials Ͼ0 mV (Fig. 4D ) yielded a value approximately equal to zero for the slope of the line: 49.5 Ϯ 4.2% of the control value at 0 mV and 46.8 Ϯ 3.2% of the control at ϩ40 mV (F 4,35 ϭ 0.09, P Ͼ 0.05).
Use-dependent inhibition of K V 1.3. Twenty repetitive 200-ms depolarizing pulses of ϩ40 mV from a holding potential of Ϫ80 mV were applied at two different frequencies, 1 and 2 Hz (Fig. 5) . Under control conditions, the peak amplitude of K V 1.3 decayed progressively, eventually reaching a steady state, and was decreased by 55.3 Ϯ 3.6% and by 71.0 Ϯ 3.9% (n ϭ 6) after the application of a train of depolarizing pulses at 1 and 2 Hz. In the presence of 5 M FK-506, the peak amplitude of K V 1.3 progressively decreased, reaching a steady-state inhibition after approximately six depolarizing pulses. The extent of the steady-state inhibition was 88.0 Ϯ 2.9% and 94.7 Ϯ 1.6% (n ϭ 6) at 1 and 2 Hz, respectively. Thus FK-506 exhibited a strong use-dependent inhibition of K V 1.3.
Effects of FK-506 on steady-state inactivation of K V 1.3. To characterize the inhibitory effects of FK-506 on K V 1.3, we examined the voltage dependence of the steady-state inactivation curve of K V 1.3 (Fig. 6A) . Under control conditions, the potential corresponding to the half-inactivation point (V 1 ⁄2) was Ϫ42.8 Ϯ 0.7 mV and slope factor k was 2.84 Ϯ 0.07 mV (n ϭ 8). FK-506 shifted the steady-state inactivation curves (V 1 ⁄2) to a hyperpolarized potential in a concentration-dependent manner (Ϫ52.3 Ϯ 0.5 mV at 5 M, Ϫ56.9 Ϯ 1.1 mV at 30 M FK-506; F 2,21 ϭ 74.8, P Ͻ 0.001). In the presence of FK-506, however, the slope factor was not significantly changed (2.81 Ϯ 0.06 mV at 5 M, 2.85 Ϯ 0.11 mV at 30 M FK-506; F 2,21 ϭ 0.05, P Ͼ 0.05). The inhibition, measured as the reduction in the steady-state current in the presence of FK-506 (the IC 50 value obtained from concentration-response data as shown in Fig. 1 ), does not represent the true affinity of the drug for the inactivated states of K V 1.3. Thus the apparent K i for the inhibition of K V 1.3 by FK-506 in the inactivated state was estimated from the concentration-dependent shift in the steady-state inactivation curve (2) . The theoretical value of K i was calculated to be 0.37 Ϯ 0.08 M (n ϭ 8; Fig. 6B ). Thus the effect of FK-506 on channel inactivation is 15 times more potent than on the steady-state current.
Effects of FK-506 on recovery from inactivation of K V 1.3.
Recovery from FK-506-induced inhibition was measured with a double-pulse protocol. Figure 7 shows the peak current amplitudes elicited by the test pulses as a function of the time interval. Under control conditions, the recovery from inactivation could be described by a biexponential function to a fast time constant of 0.65 Ϯ 0.34 ms and a slow time constant of 7.01 Ϯ 0.55 ms (n ϭ 5). In the presence of 5 M FK-506, the recovery process was also best fitted with a biexponential function (fast time constant of 0.62 Ϯ 0.19 ms, slow time constant of 18.17 Ϯ 3.69 ms; n ϭ 5). The fast time constant obtained in the presence of FK-506 remained unchanged, but the slow time constant was statistically different from that for the current recovery under control conditions (F 1,8 ϭ 8.97, P Ͻ 0.05). Figure 8 shows the effects of FK-506 on K V 1.3 currents recorded from inside-out patches. In the presence of 5 M FK-506, inhibition of the K V 1.3 currents was also characterized by an acceleration in the apparent rate of current decay with little effect on peak amplitude, as was found in whole cell recordings (Fig. 1) . FK-506 (5 M) inhibited the steady-state current of K V 1.3 at the end of a depolarizing pulse of ϩ40 mV by 54.9 Ϯ 2.7% of the control value (n ϭ 7), similar to 58.2 Ϯ 6.7% (n ϭ 9) of the control obtained for whole cell patches. Figure 9A shows superimposed K V 1.5 current traces produced by 250-ms depolarizing pulses to ϩ40 mV under control conditions and in the presence of various concentrations of FK-506. Similar to K V 1.3, FK-506 also induced a reduction in the steady-state current of K V 1.5 during the depolarizing pulse, with little effect on peak amplitude. The current amplitude, measured at the end of the 250-ms depolarizing pulse, was also used as an index of the inhibition. A nonlinear least-squares fit of the individual data points to the Hill equation yielded an IC 50 value of 4.6 Ϯ 0.1 M and n H of 1.2 Ϯ 0.1 (n ϭ 5). We further characterized the effect of FK-506 on K V 4.3, a rapidly inactivating A-type current. As shown in Fig. 9B , FK-506 decreased the peak amplitude of K V 4.3 in a concentration-dependent manner. However, the most obvious effect of FK-506 was an acceleration in the rate of the current decay of K V 4.3. To quantify the effect of FK-506 on K V 4.3, therefore, we measured the integral of the total current over the duration of a depolarizing pulse to ϩ40 mV and obtained an IC 50 value of 53.9 Ϯ 4.6 M and n H of 0.9 Ϯ 0.1 (n ϭ 8).
Effects of FK-506 on K V 1.3 in inside-out patches.
Concentration-dependent inhibition of K V 1.5 and K V 4.3 by FK-506.
DISCUSSION
The primary focus of this study was to determine the direct effect of FK-506 on the cloned voltage-gated K ϩ channels K V 1.3, K V 1.5, and K V 4.3. The findings indicate that FK-506 caused a reversible time-, concentration-, and use-dependent inhibition of K V 1.3 channels. These results suggest that FK-506 inhibits K V 1.3 by mechanisms that do not involve the suppression of the protein phosphatase activity of calcineurin but by a distinct mechanism involving a direct interaction with K V 1.3 channels. This is the first report of such a novel pharmacological property of FK-506 on K V 1.3.
FK-506 is used as an immunosuppressant in organ transplantation and in the treatment of autoimmune diseases (13, 26, 38) . The mechanism of its immunosuppressive action is thought to be mediated by a calcineurin-dependent mechanism (23, 36, 45) . The findings here, however, indicate that FK-506 directly inhibits K V 1.3 currents by a mechanism that is independent of calcineurin activity, based on the following results. First, rapamycin is another macrolide immunosuppressant drug, and its mechanism of action is different from that of FK-506. Rapamycin has no effect on calcineurin but suppresses later events in signal transduction pathways that are responsible for IL-dependent T lymphocyte activation (1, 36) . From an analysis of the concentration-response curve, however, the potencies of rapamycin and FK-506 in inhibiting K V 1.3 were very similar. The fact that rapamycin and FK-506 have similar structures suggests that this effect might be due to structural similarities rather than the modification of the signal transduction pathways required for T lymphocyte activation, namely, the inhibition of calcineurin activity. Thus we suggest that FK-506 and rapamycin share a common mechanism of action at the molecular level: direct interaction with the K V 1.3 channel. Second, in our experiments, the presence of cypermethrin in the bath solution or calcineurin autoinhibitory peptide in the patch pipette failed to prevent the inhibition of K V 1.3 by FK-506. Because the concentrations of calcineurin inhibitors used in this experiment were sufficiently high to completely inhibit calcineurin activity (12, 15) , these results are incompatible with phosphorylation events due to the inhibition of the phosphatase activity of calcineurin by FK-506. Third, the catalytic activity of calcineurin requires a significant increase in the concentration of intracellular free Ca 2ϩ (39) .
Our experiments were performed in whole cell recordings in which free Ca 2ϩ was buffered by EGTA (10 mM) to resting concentrations (Ͻ10 nM), and low levels of calcineurin activity would be expected in CHO cells. Thus our experimental conditions support a scenario involving the calcineurin-independent inhibition of K V 1.3 by FK-506. However, we cannot completely rule out the possibility that calcineurin-dependent effects may still exist. Finally, in an excised inside-out patch devoid of diffusible cytosolic molecules required for phosphorylation and dephosphorylation, the rapid and reversible effect of FK-506 was also consistent with a direct interaction with the K V 1.3 channel rather than through a phosphorylation-dependent mechanism. In addition, the rapid onset and reversibility of the inhibition of K V 1.5 in whole cell recordings indirectly suggest that the inhibition is not related to phosphorylation. K V 1.3 is a delayed-rectifier K ϩ channel and inactivates over hundreds of milliseconds during prolonged depolarization. Moreover, the recovery from inactivation is extremely slow, and inactivation accumulates in response to a train of repetitive depolarizing pulses (25) . Consequently, the presence of a cumulative inactivation in K V 1.3 channels can make a significant contribution to controlling membrane potentials. Our data suggest that FK-506 not only accelerated the time course for the intrinsic inactivation of K V 1.3 currents but also shifted the voltage dependence of steadystate inactivation in the hyperpolarizing direction. In addition, the inhibition of K V 1.3 by FK-506 was voltage dependent, increasing in the voltage range for channel activation. This reflects the voltage dependence of channel inactivation but is not due to a direct voltage dependence of binding to K V 1.3 channels. These effects probably result from the preferential interaction of this drug with the inactivated state of the K V 1.3 channel. Consistent with this, the inhibitory effect of FK-506 was use dependent, with the effects enhanced at higher rates of channel activation. A possible mechanism of action is that FK-506 is highly lipophilic (36) and is readily partitioned into the plasma membrane, thereby modulating the inactivation kinetics of K V 1.3 by an allosteric mechanism. FK-506 binding to inactivated K V 1.3 channels stabilizes the inactivated state, and thus decreases the current after steady-state inactivation at any given potential. Under these conditions, the availability of K V 1.3 channels is decreased when sustained depolarization occurs in the case of nonexcitable cells, such as T lymphocytes. Thus the state-dependent inhibition by FK-506 seems suited to producing a prolonged nonconducting inactivated state of K V 1.3 from which they recover with a time constant of several seconds.
In human T lymphocytes, K V 1.3 is the predominant voltagegated K ϩ channel. This channel plays an important role in the physiology of T lymphocytes, i.e., indirectly modulating Ca 2ϩ signaling by regulating their membrane potential (3, 9) . The selective blockade of K V 1.3 inhibits T lymphocyte activation by depolarizing the membrane potential of the cells, thereby attenuating the Ca 2ϩ signaling response. Previous studies have indicated other possible immunosuppressive effects of margatoxin, a specific K V 1.3 blocker, such as inhibiting the production of Th-1-, Th-2-, IL-2-, and T lymphocyte-mediated cytolysis, in addition to inhibiting T lymphocyte activation (22, 34) . Therefore, selective blockers of K V 1.3 have consistently been of interest and are considered to be an important therapeutic target for immunosuppressive drugs and autoimmune diseases (14) . In the present study, FK-506 inhibited K V 1.3 in a concentration-dependent manner. The depolarization of T lympho- cytes by FK-506 was also observed by electrophysiology in membrane potential measurements (31) . Therefore, this inhibitory effect of FK-506 on K V 1.3 channels, which results in the membrane depolarization of T lymphocytes, could be another underlying mechanism by which FK-506 exerts its immunosuppressive effect.
Although FK-506 is used extensively as an immunosuppressive agent in human organ transplantation, it causes numerous side effects including nephrotoxicity, hypertension, and neurotoxicity (13, 38) . Moreover, secondary toxic effects have been reported in cardiac tissue, such as arrhythmia and heart failure. K V 1.5 has been postulated to be the predominant delayed-rectifier K ϩ current responsible for human atrial repolarization (43) . K V 4.3, a rapidly inactivating A-type current, is expressed at high levels in the heart and is responsible for the early repolarization of the cardiac action potential (28) . Theoretically, the inhibition of K V 1.5 and/or K V 4.3 delays the repolarization of cardiac action potentials. Several studies have reported ventricular tachycardia in patients receiving FK-506, and its putative mechanism involves retarding ventricular repolarization (18, 19) . Therefore, it would be expected that, in patients treated with FK-506, arrhythmia may result, at least partly, from the direct interaction of FK-506 with K V 1.5 and/or K V 4.3 of cardiomyocytes.
The therapeutic plasma concentration of FK-506 is in the range of 0.5-1.5 nM in transplant patients (20) . We estimated the K i for binding to the inactivated state of K V 1.3 to be 0.37 M, which is well above the therapeutic dose, and this effect appears to have no clinical relevance. However, the concentration of FK-506 in blood is up to 100-fold higher than that in plasma (21) . In addition, the concentration of FK-506 in the blood does not necessarily reflect its tissue concentration, and the concentrations in target tissues themselves may be more important in terms of assessing the pharmacological action or side effects of a drug. FK-506 that is highly lipophilic and cell membrane permeant can progressively accumulate in higher concentrations in tissues including T lymphocytes (42) . Moreover, the acute cardiovascular effect of FK-506 on electrophysiological and mechanical properties in the isolated guinea pig heart was reported at a micromolar concentration (30) . Therefore, under this assumption, our results shed some light on the molecular mechanisms that underlie some of the cardiac toxicity observed in patients who are being administered FK-506.
In this study, we report on a novel calcineurin-independent pharmacological property of FK-506, the direct inhibitory effects of FK-506 on cloned K V 1.3 channels. Our findings reveal another mechanism of action of FK-506 for immune suppression.
